Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

$24.99

Economic Value Added (EVA)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Thermo Fisher Scientific Inc., economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The period under review demonstrates a consistent pattern of negative economic profit. Net operating profit after taxes (NOPAT) fluctuated over the five-year span, while the cost of capital remained relatively stable. Invested capital generally increased before declining in the most recent year. The combination of these factors resulted in a widening economic loss throughout the period.

NOPAT Trend
Net operating profit after taxes began at US$6,545 million in 2020, increased to US$7,465 million in 2021, then decreased to US$6,425 million in 2022. A more substantial decline was observed in 2023, falling to US$5,117 million, followed by a modest recovery to US$5,400 million in 2024. This indicates a volatile earnings performance.
Cost of Capital
The cost of capital exhibited minimal variation, ranging from 10.99% to 11.38% across the five years. This suggests a consistent required rate of return on invested capital. The slight increase in 2024 to 11.36% may warrant further investigation.
Invested Capital
Invested capital showed a clear upward trend from 2020 to 2023, increasing from US$61,158 million to US$85,573 million. However, a decrease to US$82,071 million was recorded in 2024. This suggests a potential shift in capital allocation strategy or divestiture of assets in the latest year.
Economic Profit
Economic profit was negative throughout the entire period, starting at a loss of US$-417 million in 2020. The loss progressively worsened, reaching US$-4,520 million in 2023, before slightly improving to US$-3,925 million in 2024. The increasing magnitude of the negative economic profit indicates that the company’s returns are consistently failing to cover the cost of capital.

The consistent negative economic profit, despite increases in invested capital for a portion of the period, suggests a potential issue with either operational efficiency or the effectiveness of capital deployment. The modest recovery in economic profit in 2024, coinciding with a decrease in invested capital, may indicate a positive, but limited, impact from capital management.


Net Operating Profit after Taxes (NOPAT)

Thermo Fisher Scientific Inc., NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net income attributable to Thermo Fisher Scientific Inc.
Deferred income tax expense (benefit)1
Increase (decrease) in allowances2
Increase (decrease) in LIFO reserve3
Increase (decrease) in accrued restructuring costs4
Increase (decrease) in equity equivalents5
Interest expense
Interest expense, operating lease liability6
Adjusted interest expense
Tax benefit of interest expense7
Adjusted interest expense, after taxes8
Interest income
Investment income, before taxes
Tax expense (benefit) of investment income9
Investment income, after taxes10
Net income (loss) attributable to noncontrolling interest
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in allowances.

3 Addition of increase (decrease) in LIFO reserve. See details »

4 Addition of increase (decrease) in accrued restructuring costs.

5 Addition of increase (decrease) in equity equivalents to net income attributable to Thermo Fisher Scientific Inc..

6 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

7 2024 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

8 Addition of after taxes interest expense to net income attributable to Thermo Fisher Scientific Inc..

9 2024 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

10 Elimination of after taxes investment income.


Net Income Attributable to Thermo Fisher Scientific Inc.
The net income shows an overall fluctuating trend during the analyzed period. It increased significantly from 6375 million US dollars in 2020 to a peak of 7725 million US dollars in 2021. However, this was followed by a decline over the next two years, reaching 5995 million US dollars in 2023. A modest recovery is observed in 2024, with net income rising to 6335 million US dollars, though it remains below the 2021 peak.
Net Operating Profit After Taxes (NOPAT)
The NOPAT values illustrate a pattern consistent with net income, with initial growth from 6545 million US dollars in 2020 to 7465 million US dollars in 2021. Subsequently, there is a notable decrease to 6425 million US dollars in 2022, followed by a sharper decline to 5117 million US dollars in 2023. A recovery phase occurs in 2024, where NOPAT increases to 5400 million US dollars, yet it still remains considerably lower than the earlier years.
Summary of Trends
The financial performance, as measured by both net income and NOPAT, peaked in 2021 and then experienced a downward adjustment for two consecutive years. Despite some recovery in 2024, neither metric returned to the highs seen in 2021. This pattern suggests a period of robust profitability followed by challenges that impacted the company’s earnings and operating efficiency, with partial improvement toward the end of the period.

Cash Operating Taxes

Thermo Fisher Scientific Inc., cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Provision for income taxes
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


The financial data reveals notable fluctuations in tax-related expenses over the five-year period ending in 2024. Two key categories, provision for income taxes and cash operating taxes, demonstrate distinct trends.

Provision for Income Taxes
The provision for income taxes exhibits significant volatility. Starting at 850 million USD in 2020, it increased sharply to 1,109 million USD in 2021. However, in 2022, the provision decreased substantially to 703 million USD, followed by a further decline to 284 million USD in 2023. A notable rebound occurs in 2024, with the provision rising again to 657 million USD. This pattern suggests variability in the company's tax liabilities or effective tax rate, possibly influenced by changes in pre-tax earnings, tax regulations, or one-time adjustments.
Cash Operating Taxes
Cash operating taxes show a generally upward trend with some minor fluctuations. Beginning at 1,227 million USD in 2020, these taxes increased substantially to 1,866 million USD in 2021. The level then remained relatively stable through 2022 at 1,806 million USD and slightly decreased to 1,701 million USD in 2023. In 2024, cash operating taxes resumed growth, reaching 1,946 million USD, the highest in the observed period. This steady increase indicates rising cash outflows for tax payments, which may reflect higher taxable income, changes in tax rates, or both.

In summary, while cash operating taxes demonstrate a mostly consistent upward trajectory, the provision for income taxes is marked by pronounced variability. The divergence in trends between these two items could imply timing differences between tax expenses recorded and actual cash paid or adjustments related to deferred taxes or tax planning strategies.


Invested Capital

Thermo Fisher Scientific Inc., invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Short-term obligations and current maturities of long-term obligations
Long-term obligations, excluding current maturities
Operating lease liability1
Total reported debt & leases
Total Thermo Fisher Scientific Inc. shareholders’ equity
Net deferred tax (assets) liabilities2
Allowances3
LIFO reserve4
Accrued restructuring costs5
Equity equivalents6
Accumulated other comprehensive (income) loss, net of tax7
Redeemable noncontrolling interest
Noncontrolling interests
Adjusted total Thermo Fisher Scientific Inc. shareholders’ equity
Construction in progress8
Investments measured at fair value on a recurring basis9
Invested capital

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of allowance for doubtful accounts receivable.

4 Addition of LIFO reserve. See details »

5 Addition of accrued restructuring costs.

6 Addition of equity equivalents to total Thermo Fisher Scientific Inc. shareholders’ equity.

7 Removal of accumulated other comprehensive income.

8 Subtraction of construction in progress.

9 Subtraction of investments measured at fair value on a recurring basis.


Total Reported Debt & Leases
The total reported debt and leases showed a significant increase from 22,545 million USD at the end of 2020 to 36,339 million USD in 2021. Subsequently, it remained relatively stable, with slight fluctuations around the 36,000 million USD mark through 2023, before decreasing to 32,775 million USD by the end of 2024. This pattern suggests a major debt acquisition or lease increase occurred between 2020 and 2021, followed by stabilization and moderate deleveraging in the final year observed.
Total Shareholders’ Equity
Shareholders’ equity demonstrated a consistent upward trend throughout the period, increasing from 34,507 million USD in 2020 to 49,584 million USD in 2024. The growth rate appears steady year-over-year, indicating sustained value creation and possible retained earnings or capital injections contributing to strengthening the equity base.
Invested Capital
Invested capital experienced a marked increase from 61,158 million USD at the end of 2020 to a peak of 85,573 million USD in 2023. However, in 2024, it declined to 82,071 million USD. The growth in invested capital through most of the period indicates expansion or investment activities, while the slight downturn in the final year could reflect divestitures, asset write-downs, or a moderation in capital expenditures.

Cost of Capital

Thermo Fisher Scientific Inc., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2024-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt obligations. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Thermo Fisher Scientific Inc., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The economic spread ratio demonstrates a consistently negative trend over the five-year period. This indicates that the company’s return on invested capital is less than its weighted average cost of capital, resulting in value destruction rather than value creation.

Economic Spread Ratio Trend
The economic spread ratio declined from -0.68% in 2020 to -5.28% in 2023, representing a substantial deterioration in economic profitability relative to invested capital. A slight improvement was observed in 2024, with the ratio increasing to -4.78%, though it remained negative.

The negative economic profit figures, ranging from US$417 million to US$4,520 million, corroborate the negative economic spread ratios. The magnitude of the economic loss increased significantly from 2020 to 2023, mirroring the worsening trend in the economic spread ratio. The decrease in economic profit in 2024 suggests a partial offset to the prior year’s loss, but the company still did not generate positive economic profit.

Invested Capital
Invested capital increased from US$61,158 million in 2020 to US$85,573 million in 2023, before decreasing slightly to US$82,071 million in 2024. This increase in capital employed, coupled with consistently negative economic profit, amplified the negative impact on the economic spread ratio.

The observed pattern suggests that while the company has been increasing its investment in operations, it has not been able to generate returns sufficient to cover its cost of capital. The modest improvement in the economic spread ratio in 2024, alongside the decrease in invested capital, may indicate early signs of improved capital allocation, but continued monitoring is necessary to confirm a sustained positive trend.


Economic Profit Margin

Thermo Fisher Scientific Inc., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Revenues
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Revenues
= 100 × ÷ =

3 Click competitor name to see calculations.


The economic profit margin demonstrates a consistently negative trend over the five-year period. Economic profit itself also exhibits a negative trajectory, increasing in absolute value over time, indicating a widening gap between the company’s cost of capital and the returns generated.

Economic Profit
Economic profit decreased from a loss of US$417 million in 2020 to a loss of US$4,520 million in 2023. A slight improvement was observed in 2024, with the loss decreasing to US$3,925 million, though remaining substantially negative.
Revenues
Revenues increased from US$32,218 million in 2020 to US$39,211 million in 2021, and further to US$44,915 million in 2022. However, revenues experienced a decline in 2023, falling to US$42,857 million, and remained relatively stable in 2024 at US$42,879 million. Despite revenue growth in the earlier part of the period, it has not translated into positive economic profit.
Economic Profit Margin
The economic profit margin deteriorated from -1.30% in 2020 to -10.55% in 2023, representing a significant decline. The margin improved marginally in 2024 to -9.15%, but remains considerably negative. This suggests that the company’s profitability, when considering the cost of capital, is worsening despite initial revenue increases.

The consistent negative economic profit margin indicates that the company is not generating returns sufficient to cover its cost of capital. While revenue increased initially, the increasing magnitude of economic losses suggests that cost of capital, operational inefficiencies, or a combination of both are impacting overall financial performance. The slight improvement in the economic profit margin in 2024, coupled with the reduced economic loss, may indicate early signs of corrective measures, but continued monitoring is necessary to assess the sustainability of this trend.